R&D | January 23, 2026
Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies
The partnership initially will focus on cardiovascular and kidney diseases
The partnership initially will focus on cardiovascular and kidney diseases
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Subscribe To Our Newsletter & Stay Updated
